ALDX

Aldeyra Therapeutics Stock Price

11.75
0.00 (0.0%)
11.75
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Aldeyra Therapeutics Inc ALDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 11.75 04:00:08
Open Price Low Price High Price Close Price Prev Close
11.75
Bid Price Ask Price Spread News
10.70 13.75 3.05 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 11.75 USD

Aldeyra Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 536.53M 45.66M 40.10M $ - $ - -2.23 -9.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Aldeyra Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.5012.7810.9011.82476,747-0.75-6.0%
1 Month12.23512.8510.1211.72778,218-0.485-3.96%
3 Months13.1114.529.9012.05879,354-1.36-10.37%
6 Months6.8314.61786.2110.51874,5454.9272.04%
1 Year3.3314.61782.507.79908,0408.42252.85%
3 Years7.0516.701.488.13522,0984.7066.67%
5 Years5.4616.701.487.96380,0516.29115.2%

Aldeyra Therapeutics Description

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.


Your Recent History
NASDAQ
ALDX
Aldeyra Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.